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SUMMARY
Author Manuscript

Dorsal raphe (DR) serotonin neurons provide a major input to the ventral tegmental area (VTA).
Here, we show that DR serotonin transporter (SERT) neurons establish both asymmetric and
symmetric synapses on VTA dopamine neurons, but most of these synapses are asymmetric.
Moreover, the DR-SERT terminals making asymmetric synapses on VTA dopamine neurons
coexpress vesicular glutamate transporter 3 (VGluT3; transporter for accumulation of glutamate
for its synaptic release), suggesting the excitatory nature of these synapses. VTA photoactivation
of DR-SERT fibers promotes conditioned place preference, elicits excitatory currents on
mesoaccumbens dopamine neurons, increases their firing, and evokes dopamine release in nucleus
accumbens. These effects are blocked by VTA inactivation of glutamate and serotonin receptors,
supporting the idea of glutamate release in VTA from dual DR SERT-VGluT3 inputs. Our findings
suggest a path-specific input from DR serotonergic neurons to VTA that promotes reward by the
release of glutamate and activation of mesoaccumbens dopamine neurons.
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INTRODUCTION
Although selective serotonin uptake inhibitors comprise the major class of modern
antidepressants, the role of serotonin in reward function remains poorly understood. Lesion
and pharmacological studies implicate serotonin in a wide array of cognitive and behavioral
functions, including mood and reward (Lucki, 1998). Alterations in serotonergic function
and reward-related processing have been hypothesized in several psychiatric disorders,
including schizophrenia (Kapur and Remington, 1996; Ziauddeen and Murray, 2010),
depression (McCabe et al., 2012; Nestler and Carlezon, 2006; Ruf and Bhagwagar, 2009;
Watson and Dawson, 2007), and drug abuse (Higgins and Fletcher, 2003; Kirby et al., 2011;
Müller et al., 2007; Vengeliene et al., 2008).
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The role of serotonin in reward-related processing has been investigated for several decades,
and although some have previously suggested that serotonin is antagonistic to reward
function, the literature describing the role of serotonin in reward is equivocal (Boureau and
Dayan, 2011; Cools et al., 2011; Hayes and Greenshaw, 2011; Kranz et al., 2010). The
inhibitory role of serotonin in reward function was initially suggested from studies showing
that depletion of serotonin increased responding for brain-stimulation reward (Phillips etal.,
1976; Poschel and Ninteman, 1971; Poschel et al., 1974) and from studies in which local
inhibition of serotonin neurons facilitated brain stimulation reward (Fletcher et al., 1995) or
established conditioned place preference (Fletcher et al., 1993). Place preference was also
observed after pharmacological manipulations aimed to inhibit serotonergic function (Liu
and Ikemoto, 2007; Shin and Ikemoto, 2010). In contrast, direct electrical stimulation of the
dorsal raphe (DR) is rewarding (Deakin, 1980; Miliaressis et al., 1975; Rompre and
Miliaressis, 1985; Simon et al., 1976; Van Der Kooy et al., 1978), and DR in vivo recordings
in monkeys (Bromberg-Martin et al., 2010; Nakamura et al., 2008) and rats (Miyazaki et al.,
2011; Ranade and Mainen, 2009) suggest that DR neurons are activated by reward and
contribute to reward function.
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Recent recordings from genetically identified serotonin neurons have provided evidence for
neuronal activation of some DR serotonin neurons in response to cues predicting reward
(Cohen et al., 2015; Liu et al., 2014) or reward consumption (Li et al., 2016). In addition,
behavioral studies have shown that photoactivation of DR serotonin neurons reinforces
instrumental behavior (Li et al., 2016; Liu et al., 2014). However, other studies have reported
that photoactivation of DR serotonin neurons do not reinforce behavior (Fonseca et al.,
2015; McDevitt et al., 2014). Because global serotonin brain manipulations can alter
multiple serotonergic projections and transduction pathways as well as multiple components
of a given aspect of reinforcement, the role of serotonin on reward function may be better
understood by studying the contribution of specific serotonergic pathways. In this regard,
DR serotonin neurons heavily innervate the ventral tegmental area (VTA) (Bobillier et al.,
1976; Pierce et al., 1976), the origin of the mesolimbic dopamine system, a network of
known importance for reward and motivational function (Wise, 2004). Immuno
ultrastructural studies have demonstrated that DR serotonin neurons establish synaptic
contacts on VTA dopamine neurons (Hervé et al., 1987; Van Bockstaele et al., 1994), and
pharmacological and electrophysiological studies have shown that serotonin is capable of
inhibiting or exciting VTA dopamine neurons. The mixed effects of serotonin on VTA
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dopamine neurons is likely to reflect activation of multiple serotonin receptor subtypes,
some of which excite or inhibit dopamine neurons (Alex and Pehek, 2007; Cameron et al.,
1997; Di Giovanni et al., 2008; Pessia et al., 1994). Nevertheless, a role of VTA in
serotonin-mediated reward was initially proposed from studies showing that infusion of
serotonin into the VTA potentiates medial forebrain bundle electrical self-stimulation
(Redgrave and Horrell, 1976).
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In the present study, we examined the ultrastructural and molecular characteristics of the
synaptic connectivity between DR serotonin neurons and VTA dopamine neurons and
determined the role of these connections in behavior. Our results demonstrate that axon
terminals from DR serotonin neurons establish symmetric or asymmetric synapses on VTA
dopamine neurons. We found that the axon terminals from DR serotonin neurons making
asymmetric (putative excitatory) synapses on VTA dopamine neurons coexpress vesicular
glutamate transporter 3 (VGluT3). VTA activation of DR serotonin terminals elicits
excitation of dopamine neurons, and the release of serotonin and glutamate from these
terminals activates serotonin and glutamate receptors, induces release of dopamine in
nucleus accumbens (nAcc), and promotes conditioned place preference (CPP).

RESULTS
SERT and Dual SERT-VGluT3 Axon Terminals Differentially Synapse on VTA Dopamine
Neurons

Author Manuscript

Tracing studies in the rat have shown that two types of DR serotonergic neurons innervate
the VTA; serotonin-only and dual serotonin-VGluT3 neurons (Geisler et al., 2007; Hioki et
al., 2010). Here, we examined, in mouse VTA, the frequency of axon terminals (punctate
structures containing synaptophysin) expressing SERT alone (SERT-only terminals) or
together with VGluT3 (SERT-VGluT3 terminals) (Figure 1A). We determined that, from a
population of 14,342 counted SERT terminals in the VTA, 67.66% ± 1.43% were SERT-only
and 32.34% ± 1.43% were dual SERT-VGluT3 terminals (Figure 1B; t(3) = 12.33, p =
0.0011).
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By triple-immunolabeling and electron microscopy, we determined the extent to which
SERT-only or SERT-VGluT3 terminals synapse on VTA dopamine neurons (expressing
tyrosine hydroxylase [TH]). Given that VGluT3 and SERT are each confined to presynaptic
compartments in VTA and TH has a postsynaptic distribution in dendrites and cell bodies
(Bayer and Pickel, 1991; Carr and Sesack, 2000; Omelchenko and Sesack, 2005), this
segregation allowed us the simultaneous detection of presynaptic VGluT3 or SERT and
postsynaptic TH. By electron microscopy, we found that terminals from both SERT-only and
SERT-VGluT3 neurons established synapses on VTA TH-neurons, but 61.17% ± 2.59%
were from SERT-VGluT3 terminals (t(3) = 4.313, p = 0.0230; 150 of 251 SERT-VGluT3
terminals) and 36.99% ± 3.72% from SERT-only terminals (36.99% ± 3.72%, t(3) = 3.498, p
= 0.0395; 180 of 535 SERT-only terminals) (Figures 1C, 1D, and S1). Furthermore, we
found that SERT-positive terminals establishing asymmetric synapses on VTA TH-positive
neurons coexpressed VGluT3, suggesting that serotonergic terminals establishing
asymmetric synapses are excitatory because of their capability to co-release glutamate.
These findings indicate that, within the VTA, TH-positive neurons are the major target of
Cell Rep. Author manuscript; available in PMC 2019 April 30.
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dual SERT-VGluT3 neurons and that most DR serotonin neurons synapsing on TH-positive
neurons are from dual SERT-VGluT3 neurons.
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We next determined whether DR-SERT-VGluT3 neurons synapse on TH neurons that
innervate nAcc (mesoaccumbens neurons). For these studies, we injected an adenoassociated virus (AAV, encoding Cre-dependent channelrhodopsin-2 [ChR2], tethered to
mCherry or enhanced yellow fluorescent protein [eYFP]) in DR of SERT::Cre mice (referred
to here as SERT-ChR2-mCherry or SERT-ChR2-eYFP mice) to drive expression of ChR2mCherryorChR2-eYFPin DR-SERT neurons (Figure 2). Next, in the nAcc of these mice, we
injected the retrograde tract tracer Fluoro-Gold (FG) to tag mesoaccumbens neurons
(Figures 2A, 2A’, and S2A). We observed that DR inputs mostly innervated the lateral VTA,
where most FG-positive neurons were detected, FG-neurons that were mostly TH-positive
(81.02%; 397 of 490 FG neurons). Then, by quadruple immunofluorescence, we found that
SERT-VGluT3 axon terminals targeted dual FG-TH dendrites, which were confined to
lateral VTA (Figures 2B–2D). By VTA electron microscopy, we confirmed that dual SERTVGluT3 axon terminals made asymmetric synapses on dendrites coexpressing TH and FG
(Figures 2E–2G). Together these fluorescence and ultrastructural findings indicate that
dopamine mesoaccumbens neurons are a major target of dual DR serotonergic-VGluT3
neurons. These anatomical findings provide evidence suggesting an excitatory control of
mesoaccumbens VTA dopamine neurons by dual SERT-VGluT3 afferents from DR neurons.
VTA Optical Activation of SERT Fibers Evokes Excitatory Currents on Mesoaccumbens
Dopamine Neurons
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Published studies using whole-cell patch-clamp recordings have shown that optical
stimulation of inputs from Pet-1 neurons (express mostly in serotonergic neurons) releases
glutamate and serotonin within the VTA (Liu et al., 2014). To directly test glutamate release
from serotonergic neurons on VTA dopamine neurons innervating nAcc, we prepared VTA
slices from SERT-ChR2-eYFP mice that were also injected in nAcc with the retrograde
tracer cholera toxin subunit B (CTb) (n =6 mice; Figures 2H and S2B). We performed patchclamp recordings from 24 CTb-labeled (mesoaccumbens) neurons distributed in the lateral
VTA and found that VTA optical stimulation of SERT-fibers evoked excitatory postsynaptic
currents (EPSCs) in seven of the CTb recorded neurons, whose currents were abolished by
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist 6cyano-7-nitroquinoxaline-2,3-dione (CNQX) (Figure 2J). We filled the recorded neurons
with biocytin and found that five CTb-recorded neurons showing optical-evoked EPSCs
were TH positive (Figure 2I). To determine whether DR-SERT inputs are capable of exciting
TH mesoaccumbens neurons, we performed VTA cell-attached and current-clamp
recordings in response to optical stimulation and found increased firing of three CTb-TH
neurons (Figure 2K). The optical-evoked EPSCs were eliminated by bath application of
tetrodotoxin (TTX; 500 nM) and were restored by application of 4-aminopyridine (4-AP;
200 μM) (Figure S3), suggesting that optical-evoked EPSCs are mediated by monosynaptic
glutamatergic transmission. These findings indicate that VTA glutamate release from DR
dual SERT-VGluT3 terminals is capable of evoking the firing of mesoaccumbens dopamine
neurons.
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In addition, by whole-cell voltage-clamp recordings, we found that either 0.5-ms pulses of
VTA electrical stimulation of DR fibers or 2-ms pulses of VTA optical stimulation of DRSERT fibers evoked EPSCs on VTA dopamine neurons, clamped at −60 mV and found that
those currents decreased after VTA blockade of 5-HT3 receptor antagonist Y-25130. As a
result of 5-TH3 receptor blockade, the current evoked by optical stimulation decreased from
63.78 ± 20.8 pA to 53.07 ± 19.22 pA (Figures 3A and 3B), and that evoked by electrical
stimulation decreased from −1,686 ± 322.7 pA to −1,511 ± 262.6 pA (Figures 3D and 3E).
The 5-HT3 receptor-mediated current was calculated by subtracting the total current from
the current remaining after 5-HT3 receptor antagonism (optical 5-HT3-mediated current =
13.14 ± 3.3 pA; electrical 5-HT3-mediated current = 80.3 ± 46.33 pA). Additionally, the rise
time of the optically evoked, 5-HT3-mediated current was faster (0.47 ± 0.094 ms) than the
remaining current (0.84 ± 0.11 ms; Figure 3C). This kinetic characteristic was also similar
for electrical stimulation, faster (0.60 ± 0.094 ms) than the remaining current (0.79 ± 0.23
ms), although that was not statistically significant (paired t test, p > 0.05, n = 3). We found
that blockade of 5-HT3 receptors increased the optically induced, paired pulse ratio (from
0.34 ± 0.1 to 0.62 ± 0.12; Figure 3F), suggesting that 5-HT3 receptors can also affect the
probability of neurotransmitter release. These findings indicate that VTA release of
serotonin from DR inputs excites dopamine neurons via activation of 5-HT3 receptors.
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By in vivo VTA recordings in urethane-anesthetized mice, we found that VTA optical
stimulation of SERT fibers evoked either neuronal excitation or inhibition (Figure 3G). From
a total of 80 VTA-recorded neurons in response to photoactivation of the DR to VTA
pathway, 20% (16 of 80) of the neurons were excited and 28.8% (23 of 80) were inhibited
(Figure 3H); the excitatory and the inhibitory responses had similar onset (reaching
significance at 1.5 s after stimulus) and duration (6.5 s from prestimulation firing rates to
onset; Figures 3I and 3J). Among the neurons that showed excitation, 50% (8 of 16)
remained excited during the 6 s immediately after the stimulus, and in only one of those
neurons was the excitation followed by inhibition (Figure 3I, individual traces). Among the
neurons that were inhibited, 44% (10 of 23) remained inhibited during the 6 s immediately
after the stimulus, and in 21.8% (5 of 23) of those neurons, the inhibition was followed by
excitation (Figure 3J, individual traces).
These findings from in vitro and in vivo VTA recordings, together with those from immuno
ultrastructural studies (Figures 1C and 1D), indicate that (1) some SERT inputs from DR to
VTA release glutamate, and (2) DR dual SERT-VGluT3 terminals establish asymmetric
synapses, mostly on TH neurons, and have an excitatory effect on some dopamine neurons
that innervate the nAcc.
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DR-SERT Inputs Targeting VTA Promote nAcc Dopamine Release
We next determined whether stimulation of DR neurons or their VTA inputs produce release
of dopamine in nAcc. We first tested the effects of DR electrical stimulation on nAcc
dopamine release (Figures S4A–S4D) because previous studies had reported that electrical
stimulation of DR inhibits dopamine neurons (Dray et al., 1976; Trent and Tepper, 1991;
Tsai, 1989). In contrast with previous, published findings, we found that DR electrical
stimulation evoked rapid and robust release of dopamine in nAcc core, as measured by fast-
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scan cyclic voltammetry (Figure S4). We administered the D2-receptor antagonist eticlopride
(2 mg/kg, intraperitoneally [i.p.]) to confirm that the principal electrochemical contribution
to the signal was from dopamine. Eticlopride treatment significantly increased the signal due
to autoreceptor blockade (Figures S4B and S4C), suggesting that the recorded
electrochemical analyte was dopamine. Additionally, we did not detect changes in the rate of
decay of the signal in the nAcc of animals that received systemic administration of the
serotonin reuptake inhibitor fluoxetine (10 mg/kg, i.p.), suggesting that serotonin was not
released in a detectable fashion in the nAcc core after DR stimulation (Figure S4D). Because
previous in vivo microdialysis studies have shown that 5-HT3 receptors affect dopamine
release within the mesoaccumbens system (Campbell et al., 1996; Imperato and Angelucci,
1989; McBride et al., 2004), we tested the effect of ondansetron on evoked accumbal
dopamine release driven by DR electrical stimulation. We found that the baseline (predrug)
level of dopamine release in nAcc core evoked by DR electrical stimulation (Figures S4E–
S4G; 141.9 ± 8.8 nM, n = 4) was significantly reduced by systemic application of
ondansetron (2 mg/kg i.p.) (Figure S4E; 89.4 ± 5.0 nM, p < 0.01, n = 4). Importantly, we
recapitulated the findings obtained after systemic pharmacology by demonstrating a
significant reduction of dopamine release following intra-VTA microinjections (3 μg/0.3 μL)
(Figures S5A and S5B) of either ondansetron (42.3% ± 2.9%) or CNQX (47.3% ± 1.9%;
Figures S4H and S4I). Together, these results suggest that DR excitatory effects on VTA
through 5-HT3 and glutamatergic receptors drive mesoaccumbens release of dopamine. We
next measured nAcc dopamine release in the nAcc core, as evoked by VTA optical
stimulation of DR-SERT inputs (Figures 4A–4D, S5C, and S5D‘). Dopamine release in the
nAcc core evoked by optical stimulation of DR-SERT neurons (54.8 ± 2.9 nM) or SERT
fibers in VTA (38.9 ± 5.9 nM) was significantly increased after systemic application of
eticlopride (2 mg/kg i.p.) (Figure 4D; 99.6 ± 9.8 nM for stimulation of DR, 115.3 ± 11.8 nM
for stimulation of VTA SERT fibers).
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In a follow-up study, we evaluated dopamine release in nAcc of freely moving mice by
microdialysis coupled to electrochemical detection (Figures 4E and 4F). We found that
basal, extracellular nAcc dopamine levels were not significantly different between SERTeYFP control mice (0.39 ± 0.01 nM, n = 6) and SERT-ChR2-eYFP mice (0.38 ± 0.02 nM, n
= 18). Consistent with results from the fast-scan cyclic voltammetry, we found that VTA
optical stimulation of SERT fibers significantly increased dopamine concentrations in nAcc
(Figure 4F). To determine whether 5-HT3 receptors or glutamate receptors on VTA
dopamine neurons mediated that effect, we injected 0.2 μL of ondansetron (3 μg) in the VTA
of SERT-ChR2-eYFP mice or 1 μg of CNQX 10 min before photostimulation. Dopamine
release induced by VTA photostimulation of SERT fibers was blocked by both ondansetron
and CNQX, but was unaffected by artificial cerebrospinal fluid (ACSF) (Figures 4F and
S5E–S5G). These findings confirm that the 5-HT3 and AMPA receptor activation of
dopamine mesoaccumbens neurons by DR-SERT fibers enhances total dopamine levels in
the nAcc. Although the presence of AMPA receptors on VTA dopamine neurons is well
established, anatomical evidence for the expression of 5-HT3 receptors in VTA dopamine
neurons has not been reported, perhaps because of the lack of anti-5-HT3 receptor antibodies
capable of recognizing plasma membrane 5-HT3 receptors (Morales et al., 1998). Therefore,
we applied a combination of in situ hybridization (for detection of 5-HT3 transcripts) and
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TH immunolabeling, and we found expression of the functional subunit A (5-HT3A) of the
5-HT3 receptor in VTA TH-positive neurons (Figures 4G and 4G’). Within the VTA, we
detected the expression of 5-HT3A subunit primarily within the TH-positive neurons; more
than 80% of neurons expressing the 5-HT3A subunit were TH-positive neurons. However,
only about one-third of the population of VTA TH-positive neurons coexpressed the 5-HT3A
subunit (Table S1), indicating that the postsynaptic effect of serotonin through the 5-HT3
receptors is restricted to a subpopulation of dopamine neurons that innervate the nAcc.
Together, these results suggest (1) that VTA stimulation of DR inputs drives both serotonin
and glutamate excitatory transmission on a particular subpopulation of VTA dopamine
neurons, (2) that this transmission induces dopamine release in the nAcc, and (3) that this
increase in dopamine release is mediated by activation of 5-HT3 and AMPA receptors.
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VTA Optical Activation of SERT Fibers Promotes CPP
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Although some studies have reported that photoactivation of DR-serotonin neurons
reinforces instrumental behavior (Li et al., 2016; Liu et al., 2014), others have reported that
photoactivation of DR-serotonin neurons does not have a role in reward-seeking behavior
(Fonseca et al., 2015; McDevitt et al., 2014). However, DR activation of serotonin neurons
may result in global release of serotonin in many brain structures and activation of multiple
serotonin receptors, leading to conflicting results. To overcome those limitations, we
evaluated the behavioral consequences of selective VTA photoactivation of inputs from DRSERT neurons because the VTA contains mesolimbic dopamine neurons shown to have a
crucial role in reward and motivational function (Wise, 2004). We first evaluated neuronal
coexpression of eYFP with tryptophan hydroxylase (TPH) by immunofluorescence
microscopy in the DR of SERT-ChR2-eYFP mice (Figures 5A and S6). We found that all
eYFP-positive neurons coexpressed TPH, and most DR TPH-positive neurons coexpressed
eYFP (96.3% of TPH neurons coexpressed eYFP; n = 2,371 neurons from three mice),
indicating the specific expression of ChR2-eYFP within DR serotonin neurons. We detected
within the VTA abundant fibers (SERT inputs) from the DR eYFP-positive neurons (Figures
5B and 5B’).
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To evaluate the behavioral consequences of VTA activation of SERT fibers, we tested SERTChR2-eYFP mice in a three-chamber apparatus in which they received trains of optical
stimulation when they entered the laser-paired chamber (Figures 5C and 5D). Mice were
able to terminate the stimulation by crossing back to the connecting chamber. SERT-eYFP
(control) mice spent equal time in both laser-paired and non-laser-paired chambers, whereas
SERT-ChR2-eYFP mice spent significantly more time in the laser-paired chamber (Figure
5D). When we subsequently tested SERT-ChR2-eYFP mice in the absence of laser
stimulation, we found that they spent more time in the chamber in which they had previously
received the stimulation (Figures 5D and S6A–S6D; p < 0.05 versus nonpaired chamber;
Newman-Keuls post hoc test). Thus, SERT-ChR2-eYFP mice not only earned the
stimulation by entering the stimulation chamber when the stimulation was available but also
acquired a preference for the stimulation chamber, as reflected by the time spent on the
subsequent day when the stimulation was no longer available. VTA optical activation of
SERT fibers of SERT-ChR2-eYFP mice did not alter locomotor activity (Figures S6B, S6E,
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and S6F; p = 0.302, two-way ANOVA; n = 10). We next evaluated the effects of intra-VTA
application of 5-HT3, serotonin type 2 receptor (5-HT2; receptor present on VTA dopamine
neurons; Doherty and Pickel, 2000) or AMPA receptor antagonists on CPP induced by VTA
optical activation of SERT inputs. We injected ondansetron (3 μg/0.3 μL), 5-HT2 receptor
antagonist ketanserin (0.5 μg/0.3 μL), or CNQX (1 μg/0.3 μL) into the VTA of SERT-ChR2eYFP mice 10 min before the laser-paired training (Figure 5E). Although ACSF-injected
mice showed a preference for the laser-paired chamber during both laser-paired training day
and test day (Figure 5F), ondansetron- or CNQX-injected mice no longer preferred the laserpaired chamber during the laser-paired training day or the test day (Figures 5F and S6D). In
ketanserin-injected mice, we observed a decrease in the preference for the laser-paired
chamber during both laser-paired training day and test day, but it did not reach the level of
significance. These results suggest that VTA 5-HT3 and AMPA receptors have a critical role
in the acquisition of CPP induced by the activation of VTA inputs from DR-SERT neurons.
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Optical Activation of Either SERT Fibers or VGluT3 Fibers in the VTA Induces CPP of
Different Durations
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Author Manuscript

We have previously demonstrated that VTA activation of inputs from DR-VGluT3 neurons
induces CPP mediated by the release of glutamate on mesoaccumbens dopamine neurons
(Qi et al., 2014). Here, we compared the CPP induced by VTA optical stimulation of DRSERT fibers and those induced by VTA optical stimulation of DR-VGluT3 fibers (Figures 6
and S7). For optical stimulation of DR-VGluT3 fibers, we drove expression of ChR2
tethered to eYFP in DR-VGluT3 neurons by injecting a viral vector encoding Cre-dependent
ChR2 in the DR of neurons of VGluT3:: Cre mice (referred to here as VGluT3-ChR2-eFYP
mice; Figure 6B). We confirmed that both SERT-ChR2-eYFP and VGluT3-ChR2-eYFP
mice spent significantly more time in the laser-paired chamber. However, SERT-ChR2-eYFP
mice spent less time in the laser-paired chamber (during the 2 days of training; 51% on
training day 1 and 51% on training day 2, p = 0.000001, three-way ANOVA, n = 10) than
did VGluT3-ChR2-eYFP mice (65% on training day 1 and 70% on training day 2; p = 0.012
on training day 1; p = 0.0002 on training day 2 versus the SERT-ChR2-eYFP mice;
Newman-Keuls post hoc test) (Figure 6B). After 2 days of laser-paired training, we tested
SERT-ChR2-eYFP and VGluT3-ChR2-eYFP mice for several days without laser stimulation
(1, 4, 7, and 12 days after the last training day) to determine the duration of the preference
elicited by the laser stimulation. We found that the time spent by SERT-ChR2-eYFP mice in
the laser-paired chamber was stable for 1 wk. In contrast, the time spent by the VGluT3ChR2-eYFP mice in the laser-paired chamber gradually and significantly decreased after
each test day (Figure 6B; p < 0.01 versus training day 2; Newman- Newman-Keuls post
hoc). These results indicate that, although DR-SERT and -VGluT3 inputs to VTA induce
CPP, the rewarding effects mediated by SERT inputs are less, but they have longer duration.

DISCUSSION
Although investigated for more than 50 years, the role of serotonin in reward has remained
controversial. We hypothesize that serotonin’s role in reward depends on its individual
pathways and synaptic characteristics. Here, we demonstrate that (1) DR-serotonin neurons
provide both serotonin-only inputs, which establish symmetric synapses, and serotonin-
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glutamate inputs, which establish asymmetric synapses within the VTA; (2) axon terminals
from dual serotonin-glutamate neurons establish asymmetric synapses on VTA-dopamine
neurons that innervate the nAcc; and (3) the release of serotonin and glutamate from DR to
VTA, through the actions of glutamate and serotonin receptors, evokes nAcc release of
dopamine, is reinforcing, and establishes CPP.
Selective VTA Cellular Targeting by DR Serotonin-Only and Dual Serotonin-Glutamate
Neurons

Author Manuscript

The regulation of VTA dopamine neurons by serotonin has been the subject of debate for
several decades. It is often suggested that VTA dopamine neurons are tonically inhibited by
serotonin because the firing rate of VTA-putative dopamine neurons is increased in brains
depleted of serotonin by chemicals or in brains with DR electrolytic lesions (Guiard et al.,
2008; Hervé et al., 1979). In contrast, the increase of serotonin levels by peripheral
administration of the serotonin reuptake inhibitor fluoxetine causes a dose-dependent
inhibition of the firing rate of putative dopamine neurons in the VTA (Prisco and Esposito,
1995). Although interpretations of findings across these studies are hindered because of the
multiple projections of the serotonergic system that are affected by global brain
manipulation of serotonin levels and the lack of evidence of recorded neurons as being
dopaminergic, we provide evidence supporting a model in which DR projections from
SERT-positive neurons to VTA through the release of serotonin and glutamate exert
excitatory actions on identified mesoaccumbens dopaminergic neurons.
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The VTA is a major target of DR serotonin neurons (Bobillier et al., 1976; Hervé et al.,
1987; Pierce et al., 1976; Van Bockstaele et al., 1994). However, recent tracing studies have
demonstrated that DR serotonin-only, VGluT3-only, and dual serotonin-VGluT3 neurons
target the VTA in the rat (Geisler et al., 2007; Hioki et al., 2010; Qi et al., 2014) and in the
mouse (Qi et al., 2014). Although it has been assumed that the major input from DR to VTA
is from serotonin neurons, we have previously shown that, within the total population of DR
neurons innervating the VTA, a major population consists of VGluT3-only neurons (≈46%)
with minor populations from serotonin-only (≈13%) or dual VGluT3-serotonin neurons
(≈14%) (Qi et al., 2014). Here, we analyzed the frequency of axon terminals from both
SERT-only and SERT-VGluT3 neurons in mouse VTA and found that SERT-only axon
terminals were twice as frequent as the SERT-VGluT3 axon terminals. Although both SERTonly and SERT-VGluT3 neurons establish synapses on dopamine and nondopamine neurons,
SERT-VGluT3 neurons more frequently synapse on dopamine neurons, and SERT-only
neurons more frequently synapse on nondopamine neurons (Figures 7A and 7B). Given that,
in addition to dopamine neurons, the VTA has glutamate-only, γ-amino-butyric acid
(GABA)-only and dual glutamate-GABA neurons (Root et al., 2018), it remains to be
determined the extent to which these different subpopulation of VTA neurons correspond to
the nondopamine neurons targeted by SERT-only or SERT-VGluT3 neurons. In addition to
long-range connections, the VTA GABA and glutamate neurons establish local synapses
(Morales and Margolis, 2017; Zhang et al., 2015), whose activity may be differentially
regulated by SERT-only or SERT-VGluT3 inputs, as reflected by our in vivo VTA recordings
showing both neuronal excitation and neuronal inhibition evoked by VTA optical stimulation
of SERT fibers.

Cell Rep. Author manuscript; available in PMC 2019 April 30.

Wang et al.

Page 10

Author Manuscript
Author Manuscript

We found that, irrespective of their postsynaptic target, the SERT terminals establishing
asymmetric synapses coexpress VGluT3, and those establishing symmetric synapses lack
VGluT3 (Figures 7A and 7B). Previous studies have characterized serotonergic synapses
within the VTA as inhibitory or excitatory based exclusively on the symmetry or asymmetry
of their synaptic membrane specializations (Morales and Pickel, 2012). Moreover, there is a
prevailing view that asymmetric synapses are excitatory because of their postsynaptic
excitatory serotonergic receptors, and conversely, symmetric synapses are inhibitory because
of their postsynaptic inhibitory serotonergic receptors (Doherty and Pickel, 2000). Although
we cannot discount the possibility that different types of postsynaptic serotonin receptors
may be selectively expressed in asymmetric or symmetric synapses, our ultrastructural
findings indicate that serotonergic axons terminals making asymmetric synapses coexpress
VGluT3 protein, having the capability to co-release serotonin and glutamate. Thus, we
propose that the excitatory nature of VTA serotonergic axons establishing asymmetric
synapses is mediated, in part, by the presynaptic release of glutamate (from VGluT3containing vesicles) and the presence of postsynaptic glutamatergic receptors.
In Vivo Electrophysiological Recordings and the Role of DR in Reward
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Emerging electrophysiological evidence suggests that different DR neurons have different
roles in reward-related processes (Bromberg-Martin et al., 2010; Miyazaki et al., 2011;
Nakamura et al., 2008; Ranade and Mainen, 2009). Recordings of genetically identified DR
serotonin neurons from head-restrained mice have shown that most DR serotonin neurons
are tonically activated after reward-predicting cues in a cue-reward association task (Liu et
al., 2014). Other studies, also from head-restrained mice, have shown that nearly 40% of DR
serotonin neurons exhibit slow and subtle variations in their activity that correlate with the
amount of reward in the environment (Cohen et al., 2015). Additional findings have shown
that many DR serotonin neurons signal short-term information about upcoming rewards and
punishments with brief changes in firing rates, leading to the suggestion that DR serotonin
neurons signal reward and punishment on both slow and fast time scales (Cohen et al.,
2015). To minimize stress induced by head-restraining, which may contribute to alterations
in signaling by serotonin neurons (Luo et al., 2016), the activity of DR-serotonin neurons
has been recorded in free-moving mice by both fiber photometry and single-cell recordings
(Li et al., 2016). Photometry detection of changes in intracellular calcium showed that DRserotonin neurons respond to both reward expectation and reward consumption (Li et al.,
2016). Moreover, nearly 60% of the DR-serotonin neurons increase their firing rate tonically
when mice are anticipating the reward and fire phasically after receipt of the reward, when
multiple, single-unit recordings are employed (Li et al., 2016). These findings from DRidentified serotonin neurons indicate heterogeneity in their activity patterns in reward-related
processes, but it remains to be determined which of the recorded patterns correspond to
serotonin-only or serotonin-glutamate neurons, the brain area in which they project, and the
nature of the postsynaptic neurons.
Photoactivation of DR-serotonin neurons has been recently applied to determine their role in
reward-associated tasks (Fonseca et al., 2015; Li et al., 2016; Liu et al., 2014; McDevitt et
al., 2014; Miyazaki et al., 2014). Findings from those studies have shown that
photoactivation of DR-serotonin neurons promotes patience for future rewards (Fonseca et
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al., 2015; Miyazaki et al., 2014) and reinforces (Li et al., 2016; Liu et al., 2014) or fails to
reinforce instrumental behavior (Fonseca etal., 2015; McDevitt et al., 2014). It is unclear
whether the discrepancy on the reinforcing effects may reflect differences in experimental
conditions leading to activation of different classes of DR-serotonin neurons or serotonin
receptors involved in different behaviors (Calizo et al., 2011; Hale and Lowry, 2011;
Kiyasova et al., 2011). Because DR activation of serotonin neurons may result in global
release of serotonin in many brain structures (Ren et al., 2018) and activation of multiple
serotonin receptors, leading to conflicting results, we studied the specific ultrastructural and
functional properties of DR serotonin fibers within the VTA. We found that most DR
serotonin fibers synapsing on VTA dopamine neurons co-release glutamate, that some of
those dopamine neurons target the nAcc, and that they are excited by DR dual serotoninglutamate inputs through glutamate and serotonin receptors, excitation that results in the
rapid release of dopamine in the nAcc (Figure 7C). Furthermore, mice learn to associate the
effect of the VTA photostimulation of those DR serotonin-glutamate inputs with their
environment, and subsequently, those mice exhibit a CPP for that environment (as animals
remember the place at which they obtained such stimulation and return to it, despite the
absence of the stimulation). Although acquisition of CPP induced by VTA optical activation
of DR-SERT inputs is mediated by glutamate and serotonin receptors, future studies are
needed to determine the roles that specific neurons within the DR pathway to VTA may have
in different aspects of reward signaling. Within the VTA, in addition to the serotoninglutamate asymmetric synapses on dopamine neurons, we found the serotonin-only terminal
making symmetric synapses mostly on nondopaminergic neurons. It remains to be
determined the nature of those nondopamine neurons and their serotonin receptor
composition. Importantly, recent findings indicate that the rewarding effects observed after
DR-serotonin neuron stimulation are reduced in knockout mice depleted of VGluT3 and are
eliminated after DR chemical inhibition of serotonin production (Liu et al., 2014). These
findings underscore the participation of both serotonin and glutamate in the reward-signaling
ability of DR-serotonin neurons (Liu et al., 2014).

STAR⋆METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be
fulfilled by the Lead Contact, Marisela Morales (mmorales@intra.nida.nih.gov).
EXPERIMENT MODEL AND SUBJECT DETAILS
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Mice—C57BL/6J mice were purchased from Jackson laboratories. Serotonin transporter
(SERT)::Cre mice were purchased from Mutant Mouse Regional Resource Centers and were
breed in the NIDA/IRP animal facility, and offspring mice were genotyped by PCR using
primers to detect the presence of the Cre recombinase gene sequence (5′-CGG CAAACG
GAC AGA AGC ATT-3′) and the presence of serotonin transporter solute carrier family 6
member 4 (Slc6a4) (5′-GGT CCT TGG CAG ATG GGC AT-3′). All animal procedures
were performed in accordance with the National Institutes of Health Guidelines, and
approved by the National Institute on Drug Abuse Animal Care and Use Committee.
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Mice for anatomical studies: Eight male serotonin transporter (SERT)::Cre mice (8–12
weeks were injected Cre-inducible recombinant adeno-associated virus (AAV) vector to
genetically target channelrhodopsin2 (ChR2) expression to serotonin neurons in the dorsal
raphe nucleus (DR) of male adult SERT::Cre mice. SERT::Cre mice were injected in the DR
(bregma: AP −4.2, ML ± 0.2, DV −3.4 to the skull surface) with AAV encoding ChR2
tethered to mCherry (SERT-ChR2-mCherry) or eYFP (SERT-ChR2-eYFP). Five weeks after
viral injection into the DR, 4 of the SERT-ChR2-mCherry mice were iontophoretically
injected into nAcc with the retrograde tract tracer Fluoro-Gold (FG; 1% in cacodylate buffer,
pH 7.5) through a stereotaxically positioned glass micropipette by applying 3 mA current in
5 s pulses at 10 s intervals for 15 min (coordinates in mm relative to bregma: AP +1.4, ML
± 0.8, DV −4.8/−4.2). The micropipette was left in place for an additional 10 min to prevent
tracer backflow up the injection track after each injection. Four male C57BL/6J mice (8–12
weeks), SERT::Cre mice at 6 weeks after virus injection or 1 week after FG injection were
deeply anesthetized with chloral hydrate (35 mg/100 g) and perfused transcardially with
fixative solution [4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB, pH 7.3)
supplemented with 0.15% glutaraldehyde and 15% picric acid in 0.1 M PB for fluorescent
and electron microscopy or 4% PFA for in situ hybridization-immunohistochemistry]. For
fluorescent and electron microscopy, brains were left in fixative solution for 2 h at 4°C, 2%
PFA overnight at 4°C, rinsed with PB, and midbrains were cut into coronal serial sections
(40 mm thick) with a vibratome (VT1000S, Leica, Vienna, Austria). For in situ
hybridization-immunohistochemistry, rat brains were left in 4% PFA for 2 h at 4°C, rinsed
with PB and transferred sequentially to 12%, 14% and 18% sucrose solutions in PB, and
VTA coronal serial cryo-sections of 12 μm in thickness were prepared. All animals of the
same sex of mixed genotypes were housed in groups of up to four animals per cage in an
animal room at 22°C under a 12 h light/dark cycle (light on at 7 am), with ad libitum access
to food and water.
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Mice for electrical stimulation and optogenetic studies: For electrical stimulation studies,
fifteen male C57BL/6J mice (8–12 weeks) were used. For optogenetic studies, eighty-six
male SERT::Cre mice were injected in the DR with AAV-ChR2 tethered to mCherry (SERTChR2-mCherry mice), eYFP (SERT-ChR2-eYFP mice), or AVV encoding eYFP (SERTeYFP mice). Ten male VGluT3::Cre mice were injected in the DR with AAV-ChR2 tethered
to eYFP (VGluT3-ChR2-eYFP mice). Mice were positioned in a stereotaxic frame under
anesthesia with isoflurane (3% isoflurane in 1L/min O2 for induction and 2% for
maintenance). Two small burr holes were drilled bilaterally over the DR at the coordinates in
mm relative to bregma: AP −4.2, ML ± 0.2, DV −3.4 to the skull surface. A NanoFil syringe
was used to deliver bilaterally 0.3 μl of virus (3 × 1012 genomes/ml) into the DR at a speed
of 0.1 μl/min. For microdialysis study, six male C57BL/6J, eighteen SERT-ChR2-eYFP mice
were implanted unilaterally with a microinjection guide cannula 1 mm above the VTA (AP
−3.4, ML +0.3, DV −3.3) and a microdialysis guide cannula above the nAcc (AP +1.3, ML
+0.6, DV −3.8). Mice were allowed to recover from surgery for 7 days before microdialysis.
Mice for behavioral experiments were implanted 4–6 weeks after virus injection with a
unilateral chronic optical fiber (200 μm diameter) or guide cannula directed above the VTA.
These mice were allowed at least 10 day recovery before behavioral test. After in vivo
studies, brain sections were obtained for location examination of injection or implantation.
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Mice with incorrect virus injection, cannula or probe implantation were excluded from data
analysis. Animal procedures were approved by the NIDA and the UMBI Animal Care and
Use Committees.
Virus—Double-floxed reverse orf EF-1α::ChR2-eYFP, EF-1α-eYFP or double-floxed
reverse of EF-1α::ChR2-mCherry cassettes were packaged in AAV vectors, serotyped with
AAV1 or AAV5 coat proteins and packaged (3 × 1012 genomes/ml) by the UNC vector core
(University of North Carolina, NC) or by the NIDA/IRP optogenetics and transgenic
technology core.
METHOD DETAILS
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Fluorescence microscopy and three-dimensional analysis—Free floating coronal
vibratome sections were incubated for 1 h in PB supplemented with 4% bovine serum
albumin (BSA) and 0.3% Triton X-100. Sections were then incubated with cocktails of
primary antibodies: mouse anti-tryptophan hydroxylase antibody (T0678; Sigma-Aldrich,
St. Louis, MO, USA, 1:500 dilution); guinea pig anti-VGluT3 antibody (135204; Synaptic
System, 1:500 dilution) + rabbit anti-SERT antibody (HTT-Rb-Af560–1; Frontier Institute
Co. Ltd, 1:250 dilution) + mouse anti-synaptophysin antibody (MAB368; MilliporeSigma,
Billerica, MA,1:250 dilution); or mouse anti-TH antibody (MAB318; MilliporeSigma,
1:1000 dilution) + goat anti-GFP antibody (GFP-Go-Af1480; Frontier Institute Co. Ltd,
1:2000 dilution) + rabbit anti-FG antibody (AB153; MilliporeSigma, 1:2000 dilution) +
guinea pig anti-VGluT3 antibody (135204; Synaptic System, 1:500 dilution) overnight at
4°C. After rinsing 3 × 10minin PB, sections were incubated inAlexa Fluor 594-affiniPure
donkey anti-mouse (715–585-151; Jackson Immunoresearch Laboratories, West Grove, PA,
USA, 1:100 dilution); a cocktail of Alexa Fluor 488-AffiniPure donkey anti-guinea pig
(706–545-148; Jackson Immunoresearch Laboratories, 1:100 dilution) + Alexa Fluor 594AffiniPure donkey anti-rabbit (711–585-152; Jackson Immunoresearch Laboratories Inc.,
1:100 dilution) + Alexa Fluor 647-AffiniPure donkey anti-mouse (715–605-151; Jackson
Immunoresearch Laboratories Inc., 1:100 dilution); or a cocktail of Dylight 405-AffiniPure
donkey anti-mouse (715–475-150; Jackson Immunoresearch Laboratories, 1:100 dilution) +
Alexa Fluor 488-AffiniPure donkey anti-goat (705–545-147; Jackson Immunoresearch
Laboratories, 1:100 dilution) + Alexa Fluor 594-AffiniPure donkey anti-rabbit (711–
585-152; Jackson Immunoresearch Laboratories, 1:100 dilution) + Alexa Fluor 647AffiniPure donkey anti-guinea pig (706–605-148; Jackson Immunoresearch Laboratories,
1:100 dilution) for 2 h at room temperature. After rinsing, sections were mounted on slides
and air-dried. Fluorescent images were collected with Olympus FV1000 Confocal System
(Olympus, Center Valley, PA). Images were taken sequentially with different lasers with 100
× oil immersion objectives and z axis stacks were collected at 0.2 μm. The confocal images
were collected from 4 mice (64 × 64 × 10 μm for each image, 50 images from each mouse).
Given that both SERT and VgluT3 are detectable in axons and axon terminals, we used
synaptophysin detection to label and quantified axon terminals expressing SERT or VGluT3.
We obtained z stacks of confocal images (immunolabeled for detection of synaptophysin,
SERT and VGluT3), and processed them with the Imaris microscopy software (Bitplane
Inc., South Windsor, CT) to obtain three-dimensional quantification of axon terminals
expressing synaptophysin with SERT-alone or with SERT-VGluT3. The same confocal
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images were analyzed with the Amira microscopy software (ThermoFisher Scientific,
Waltham, MA) to obtain three-dimensional reconstruction of putative synapses.

Author Manuscript
Author Manuscript
Author Manuscript

Electron microscopy—Vibratome tissue sections were rinsed with PB, incubated with
1% sodium borohydride in PB for 30 min to inactivate free aldehyde groups, rinsed in PB,
and then incubated with blocking solution [1% normal goat serum (NGS), 4% BSA in PB
supplemented with 0.02% saponin] for 30 min. Sections were then incubated with primary
antibodies as follows: guinea pig anti-VGluT3 + rabbit anti-SERT + mouse anti-TH
antibodies (triple labeling), or mouse anti-mCherry (632543; Takara, 1:1000 dilution) +
guinea pig anti-VGluT3 + rabbit anti-TH (AB152, MilliporeSigma, 1:1000 dilution) (triple
labeling), or mouse anti-mCherry + guinea pig anti-VGluT3 + rabbit anti-Fluoro-Gold
antibodies (triple labeling). All primary antibodies were diluted in PB with 1% NGS,
incubations were for 24 h at 4°C. Sections were rinsed and incubated overnight at 4°C in the
corresponding secondary antibodies: biotinylated goat anti-rabbit antibody (PK-4001; for
SERT detection) + anti-mouse IgG coupled to 1.4 nm gold (2001; Nanoprobes Inc., 1:100
dilution for TH detection) + anti-guinea pig IgG Fab’ fragment coupled to 1.4 nm gold (for
VGluT3 detection), or biotinylated horse anti-mouse antibody (PK-4002; for mCherry
detection) + anti-guinea pig IgG Fab’ fragment coupled to 1.4 nm gold (2055; Nanoprobes
Inc., Stony Brook, NY, 1:100 dilution for VGluT3 detection) + anti-rabbit IgG coupled to
1.4 nm gold (2003; Nanoprobes Inc., 1:100 dilution forTH or Fluoro-Gold detection).
Sections were rinsed in PB, and then in double-distilled water, followed by silver
enhancement of the gold particles with the Nanoprobe Silver Kit (2012; Nanoprobes Inc.,
Stony Brook, NY) for 7 min at room temperature. Next, sections were incubated in avidinbiotinylated horseradish peroxidase complex (PK-4000 ABC kit; Vector Labs, Burlingame,
CA,1:100 dilution) in PB for 2 h at room temperature and washed in PB. Peroxidase activity
was detected by placing the sections in a solution containing 0.025% 3, 3
diaminobenzidine-4 HCl (DAB) and 0.003% hydrogen peroxide (H2O2) in PBfor 5–10 min.
Sections were rinsed with PB and fixed with 0.5% osmium tetroxide in PBS for 25 min,
washed in PBS followed by double-distilled water and then contrasted in freshly prepared
1% uranyl acetate for 35 min. Sections were dehydrated through a series of graded alcohols
and with propylene oxide. Afterward, they were flat embedded in Durcupan ACM epoxy
resin (14040; Electron Microscopy Sciences, Fort Washington, PA). Resin-embedded
sections were polymerized at 60°C for 2 days. Sections of 65 nm were cut from the outer
surface of the tissue with an ultramicrotome UC7 (Leica Microsystems Inc., Buffalo Grove,
IL) using a diamond knife (Diatome, fort Washington, PA). The sections were collected on
formvar-coated single slot grids and counterstained with Reynolds lead citrate. Sections
were examined and photographed using a Tecnai G2 12 transmission electron microscope
(Fei Company, Hillsboro, OR) equipped with a digital micrograph OneView camera (Gatan
Inc., Pleasanton, CA). Specificity of primary antibodies has been previously
described(Zhang etal., 2015).
Slice preparation and electrophysiology—Male SERT-ChR2-eYFP mice were used
to detect DR glutamatergic inputs on VTA mesoaccumbens dopamine neurons (n = 9) as
well as DR serotonin inputs on VTA dopamine neurons (n = 4). For detection of DR
glutamatergic inputs on VTA mesoaccumbens dopamine neurons, SERT-ChR2-eYFP mice
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(six weeks after virus injection) were bilaterally injected in the nAcc shell with 0.5% cholera
toxin B subunit (CTb) conjugated with Alexa Fluor® 594 (CTb-594, Life technologies,
C34777). Two to three weeks after the CTb injection, mice were deeply anesthetized with
isoflurane and decapitated. Brains were removed and tranferred to oxygenated (95% O2/5%
CO2), ice-cold N-Methyl-D-glucamin (NMDG)-based cutting solution (in mM: 93 NMDG,
2.5 KCl, 10 MgSO4, 0.5 CaCl2,1.2 NaH2PO4, 30 NaHCO3, 25 glucose, 20 HEPES, 5
sodium ascorbate, 3 sodium pyruvate; PH 7.2–7.4). Horizontal slices containing VTA (200
μM) were then obtained using a vibratome (VT1200, Leica). Slices were first incubated in
the NMDG-based solution at 34°C for 12 min, then transferred and maintained in artificial
CSF (aCSF; in mM: 126 NaCl, 3 KCl, 1.5 MgCl2, 2.4 CaCl2,1.2 NaH2PO4, 26 NaHCO3,11
glucose) at room temperature. During recording, a midbrain slice was transferred to a heated
chamber (32°C) and perfused with oxygenated aCSF (2 ml/min). Slice was visualized under
an upright microscope equipped with differential interference contrast (DIC) optics
(BX51WI, Olympus). VTA CTb labeled neurons found close to the medial terminal nucleus
of the accessory optical tract (MT) were recorded. Cell-attached and whole-cell recordings
were performed using MultiClamp 700B (Molecular Devices) amplifier. Recording
electrodes (3~5 MΩ) were filled with a standard internal solution (in mM: 140 K-gluconate,
2 NaCl, 1.5 MgCl2, 10 HEPES, 0.1 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 10 Trisphosphocreatine, pH 7.2, 290 mOSM) supplemented with 0.2% biocytine. This Kgluconate-based low Cl− internal solution preserves cell body TH-protein during the wholecell recording, thus we can identify dopamine neurons reliably by
immunohistochemistry(Margolis et al., 2010). A 200 μm core optical fiber, coupled to a
diode-pumped solid-state laser, was positioned just above the slice and aimed at the
recording area to deliver 473 nm optical stimulation (3–5 ms pulses, 5–8 mW). Drugs were
diluted and applied through the perfusion aCSF. Slices were fixed after recording with 4%
PFAover night at 4°C. Slices were incubated with mouse anti-TH (1:500, EMD Millipore,
MAB318) primary antibody for over 2 nights at 4°C. After rinse in PB, slices were
incubated with DyLight 405 AffiniPure Donkey Anti-Mouse IgG (715–475-151; Jackson
ImmunoResearch Laboratories, 1:200 dilution) and Cy5 Streptavidin (016–170-084; Jackson
ImmunoResearch Laboratories, 1:500 dilution) over night at 4°C. Florescent images were
taken with Olympus FV1000 confocal microscope. For detection of DR serotoninergic
inputs on VTA dopamine neurons, VTA DA neurons were first identified by their location
relative to the MT, interpeduncular fossa and medial lemniscus. Additionally, cells satisfied
the following electrophysiological criteria: hyperpolarization-activated inward current (Ih),
1–5 Hz firing frequency, action potential half-width ≥ 1.5 ms, spike frequency adaptation
and spike failure during prolonged injection of depolarizing current(Goertz et al., 2015). The
presence of Ih is a partial predictor of dopaminergic identity for cells in the VTA(Margolis et
al., 2006). Recording pipettes had a tip resistance between 3–7 MOhm and were filled with
(in mM): 135 CsCl, 2 MgCl2,10 HEPES, 5 QX-314, 5 EGTA, 2 Na-ATP, 0.2 Na-GTP. Cells
were voltage clamped at −60 mV and EPSCs were evoked using a 200 μm optical fiber
coupled to a 473 nm laser or with a 250μm tungsten bipolar electrode. The optical fiber was
placed within the bath and aimed at the site of recording, and was used to deliver optical
stimulation of 1mW intensity. To test the use of optical stimulation in measuring pairedpulse ratios of EPSCs, we verified that increasing light intensity and pulse duration caused a
decrease in onset latency with an increase in amplitude. Increasing light intensity and pulse
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duration augments afferent fiber recruitment, thus increasing EPSC amplitude and
decreasing onset latency. This suggests that at lower intensity and pulse duration optogenetic
stimulation evokes EPSCs via propagating action potentials(Tecuapetla et al., 2010). The
bipolar electrode for electrical stimulation was used to deliver 0.5 ms pulses. Following a
10-minute stable baseline period, 5-HT currents were blocked by bath application of 1 μM
Y-25130 (5-HT3 receptor antagonist) and data were collected for a minimum 10 minutes. To
quantify the effect of Y-25130, sweeps were averaged for the last 5 minutes of the pre- and
post-drug phases of the experiment.
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In vivo electrophysiology—Male SERT-ChR2-eYFP mice (n = 6) were anesthetized
with urethane (1.4 g/kg, i.p.), and mounted in a stereotaxic frame. A hole was drilled in the
skull to access VTA. Glass micropipettes (6–10 MU) filled with 2.0% Pontamine Sky Blue
(BDH Chemicals, Poole, England) in 3M NaCl were used for recordings. Glass electrodes
were utilized to shield against any potential light-induced artifacts that can be observed with
metal electrode recordings alone(Cardin et al., 2010). A 100 μm core multimode fiber was
glued 350 μm dorsal to the glass electrode tip, and the fiber was connected to a 473 nm
DPSS laser (OEM laser systems, Bluffdale, UT). Signals were amplified using a Neuro Data
IR283A (Cygnus Technology, Delaware Water Gap, PA) and BrownLee 440 amplifier.
Neuronal activity was bandpass filtered between 300 Hz and 3000 Hz. The biopotentials
were digitized using a Power 1401 Analog-Digital Converter (Cambridge Electronic Design,
Cambridge UK). Spontaneously active or optogenetically-driven neurons were recorded and
analyzed. VTA recordings were obtained between −3.1 to −3.5 mm AP, 0 to 0.5 mm ML and
−4.2 to −4.6 mm DV. Entrance into the VTAwasdemarked by passage through a layer of fast
firing neurons dorsal to the VTA. Neurons were randomly sampled by slowly lowering the
micropipette through the VTA. Baseline activity was recorded for 3 to 5 min, DR fibers were
activated for 6 s at 20 Hz with 5 mW 4 ms light pulses. Peristimulus time histograms were
constructed at 500 ms resolution bins, with a window width of 6 s before and 12 s after the
stimulus onset. PSTHs were analyzed to determine excitatory and inhibitory responses. The
6 s before the stimulation were compared with the 6 slight stimulation using theWilcoxon
signed-rank test. Signal to noise ratio were typically >5:1. After recordings, animals were
perfused with 4% PFA, DR and VTA cryosections (30 μm) were prepared to verify the
deposit of the pontamine sky in the recording sites and the expression of ChR2-eYFP in cell
body and terminals. Neurons recorded external to the VTA were excluded from the analysis
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In vivo electrical stimulation and fast scan cyclic voltammetry (FSCV)—Male
C57BL/6J mice (n = 15) were positioned in a stereotaxic frame under anesthesia with
urethane (1.5 g/kg weight). A carbon fiber microelectrode (glass-encased, T-650 carbon
fiber, 6 μm diameter with 100–120 μm exposed length, Amoco Corporation, Greenville, SC,
USA) was implanted in the nucleus accumbens core (coordinates in mm relative to bregma:
AP +1.2, ML +1.1, DV −3.7 to the brain tissue surface). A bipolar stimulating electrode was
implanted in the ipsilateral DR (coordinates in mm relative to bregma: AP −4.2, ML +0.2,
DV −3.4). An Ag/AgCl wire that served as the reference electrode was implanted into the
contralateral hemisphere. Extracellular levels of dopamine in the nAcc core were monitored
by in vivo FSCV in response to 60 Hz for 2 s electrical stimulation (biphasic stimulating
pulses, 4 ms and 300 μA each phase) of the DR, parameters previously shown to induce 5-
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HT release in the midbrain(Hashemi et al., 2009). For FSCV, a triangular waveform from
−0.4 V to +1.3 V and back to −0.4 V at 400 V/s (versus the implanted Ag/AgCl reference
electrode) was applied through the carbon fiber electrode. Stimulation-evoked release of
dopamine was recorded during and after DR stimulation, and selectivity for the detected
dopamine signal was verified by intraperitoneal (i.p.) injection of a D2 receptor antagonist
(eticlopride, 2 mg/kg), that augmented the signal. The selective serotonin reuptake inhibitor
fluoxetine (10 mg/kg) was also systemically injected to determine the possible contribution
of serotonin to the recorded signal. While the cyclic voltammograms for norepinephrine and
dopamine are similar, norepinephrine is unlikely to be a significant contributor to the signal
because dopamine-β-hydroxylase is not detectable in this region(Baldo et al., 2003). At the
end of each experiment, the site of stimulation was marked by passing 20 s DC anodal
current of 300 μA. Carbon fiber microelectrodes were calibrated in vitro with a solution of
dopamine (1 μM).
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The participation of serotonin type (5-HT3) receptors in the release of dopamine in the nAcc
core in response to DR electrical stimulation was initially tested by i.p. injection of
ondansetron (5-HT3 receptors antagonist, 2 mg/kg). Four baseline voltammograms were
taken before and after DR electrical stimulation prior to ondansetron injection. Fifteen
minutes after injection, additional voltammograms were recorded at 5 min intervals during
and after DR electrical stimulation fora total period of 45 min, followed by injection of
eticlopride (2 mg/kg, i.p.) to confirm the nature of the recorded signals. The participation of
VTA5-HT3 and AMPA receptors in the release of dopamine in the nAcc core evoked by DR
electrical stimulation was tested by VTA microinjections (3 μg/0.3 μl) of ondansetron or the
AMPA receptor antagonist CNQX. Dopamine oxidation currents were transformed to
concentration using a flow injection system that delivered a square pulse of 1 μM. A guide
cannula was implanted above the VTA, and an Ag/AgCl wire was implanted into the
contralateral hemisphere. A 33-gauge microinjector was inserted 0.5 mm below the tip of
the guide cannula. The infusion lasted 1 min using a microprocessor-controlled infusion
pump. The microinjector was removed at 1 min after infusion, and accumbal dopamine
release was measured by FSCV in 5 minutes, and every 5 min during and after DR electrical
stimulation for a total period of 25 min. Dopamine selectivity of the recorded signal was
verified by FSCV measurement of accumbal dopamine evoked 15 min after eticlopride
injection (2 mg/kg, i.p.), monitored every 5 min during and after DR electrical stimulation
for a period of 15 min.

Author Manuscript

In vivo optical stimulation and FSCV—Six to eight weeks after virus injection, SERTChR2-mCherry mice (n = 8; 4 mice for optical stimulation of DR neurons and 4 mice for
optical stimulation of VTA serotonergic inputs) were positioned in a stereotaxic frame under
anesthesia with urethane. A 10 mm longitudinal incision on the skin in the dorsum of the
cranium was made to perform a craniotomy, and allowing access to the DR or VTA. A 200
μm core optical fiber (Thorlabs, Newton, NJ) was inserted and a train of blue light (473 nm
wavelengths, 20 mW, 4 ms duration/pulse, 120 pulses, 20 Hz) was delivered through the
optical fiber. Extracellular dopamine in the nAcc core was monitored by FSCV (as describe
for electrical stimulation) every 15 min during and after DR optical stimulation, and
dopamine signal selectivity was verified by i.p. injection of eticlopride. Expression of ChR2-
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mCherry was verified at the end of each experiment by fluorescent mCherry
immunodetection.
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In vivo optical stimulation, microdialysis and quantification of DA—A
microdialysis probe (0.24 × 1 mm, CMA7, CMA Microdialysis) was inserted into the guide
cannula implanted in the nAcc of wild-type (n = 6) or SERT-ChR2-eYFP (n = 18) mice in
the evening before testing. The inlet tubing of the probe was connected to a microinfusion
pump (CMA 100) via a fiber-optic and liquid rotary joint (Doric Lenses), and animals were
placed into chambers (20 × 30 × 35 cm). Probes were perfused with ACSF (in mM: 140
NaCl, 2.7 KCl, 1.2 MgCl2, 1.4 CaCl2, 5 glucose, adjusted to pH 7.3–7.4 using NaOH)
overnight at a flow rate of 0.2 μl min-1. The following day, an optical fiber was inserted into
the VTA through the guide cannula, and perfusate was replaced with fresh ACSF at the flow
rate of 2.4 μl min-1. Following a 3-h equilibration period, microdialysis samples were
collected every 10 min into 5 μl 0.1 M perchloric acid to prevent DA degradation. Three 10min samples were collected to determine the baseline of DA release in nAcc. Optical
stimulation was delivered via optical fiber into the VTA for 10 min (473 nm, 20 mW, 10 ms,
20 Hz, 3 s on/off). To test the involvement of VTA glutamate AMPA or 5-HT3A receptors,
after the optical stimulation, three consecutive samples were collected before microinjection
with ACSF, CNQX (1 μg/0.2 μl), or ondansetron (3 μg/0.2 μl) (n = 6 each group) into the
VTA. One 10 min sample was collected after the microinjection followed by another 10-min
optical stimulation in the VTA. Three more consecutive samples were collected after the
optical stimulation. DA concentration was measured by reverse-phase HPLC with
electrochemical detection. Dialysate was injected into an Eicom HTEC-500 HPLC system
containing a HPLC column (PP-ODS2, 4.6 × 30 mm), a HTEC-500 pump, and an integrated
amperometric detector. The mobile phase consisted of (in mM) 100 NaH2PO4, 1.3 EDTA,
2.0 decane-1-sulfonate, 0.5% methanol, pH 5.4. Applied potential was set at +400 mV
versus Ag/AgCl. Concentration of dialysate DA levels were estimated using calibration
curves obtained from external standards. Detection limit of DA using these conditions was
approximately 50 pM.
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Combination of in situ hybridization and immunolabeling—Coronal free-floating
sections from 3 rats (12 μm in thickness) were processed as described previously(Wang and
Morales, 2008). Brain sections were incubated for 10 min in PB containing 0.5% Triton
X-100, rinsed 2 × 5 min with PB, treated with 0.2 N HCl for 10 min, rinsed 2 × 5 min with
PB and then acetylated in 0.25% acetic anhydride in 0.1 M triethanolamine, pH 8.0 for 10
min. Sections were rinsed 2 × 5 min with PB, fixed with 4% PFA for 10 min. Prior to
hybridization and after a final rinse with PB, the free-floating sections were incubated in
hybridization buffer (50% formamide; 10% dextran sulfate; 5 × Denhardt’s solution; 0.62 M
NaCl; 50 mM DTT; 10 mM EDTA; 20 mM PIPES, pH 6.8; 0.2% SDS; 250 μg/ml salmon
sperm DNA; 250 μg/ml tRNA) for 2 h at 55°C. Sections were hybridized for 16 h at 55°C in
hybridization buffer containing [35S]- and [33P]-labeled single-stranded antisense or sense of
rat 5-HT3A (nucleotides104–1561, Accession # NM 024394.2) probes at 107 cpm/ml.
Sections were treated with 4 μg/ml RNase A at 37°C for 1 h, washed with 1 × SSC, 50%
formamide at 55°C for 1 h, and with 0.1 × SSC at 68°C for 1 h. After the last SSC wash,
sections were rinsed with PB and incubated for 1 h in PB supplemented with 4% BSAand

Cell Rep. Author manuscript; available in PMC 2019 April 30.

Wang et al.

Page 19

Author Manuscript

0.3% Triton X-100. This was followed by the overnight incubation at 4°C with an anti-TH
mouse monoclonal antibody (MAB318; EMD Millipore, 1:500 dilution). After rinsing 3 ×
10 min in PB, sections were processed with an ABC kit (Vector Laboratories, Burlingame,
CA). The material was incubated for 1 h at room temperature in a 1:200 dilution of the
biotinylated secondary antibody, rinsed with PB, and incubated with avidin-biotinylated
horseradish peroxidase for 1 h. Sections were rinsed and the peroxidase reaction was then
developed with 0.05% DAB and 0.003% H2O2. Free-floating sections were mounted on
coated slides. Slides were dipped in Ilford K.5 nuclear tract emulsion (Polysciences, Inc.,
Warrington; 1:1 dilution in double distilled water) and exposed in the dark at 4°C for four
weeks prior to development.
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CPP—SERT-ChR2-eYFP(n = 51), VGluT3-ChR2-eYFP (n = 10) and SERT-eYFP mice (n
= 11) were used for behavior studies. A three-chamber CPP apparatus was used for the test
(Anymaze, Wood Dale, IL), which consisted of two chambers (20 × 18 × 35 cm) with
distinct walls drawings floor and shape, and a connecting chamber (20 × 10 × 35 cm). We
recorded all animal movements via a CCD camera interfaced with a video tracking software.
The CPP paradigm consisted of five or eight days. On each day, the mice were connected to
an optical fiber and allowed to access three chambers freely. On habituation and pretest day
(15 min sessions), the animals were allowed to explore the apparatus without optical
stimulation. On laser conditioning days 1 and 2 (30 min sessions), we assigned one chamber
as the laser-paired chamber (counterbalanced across all mice). The animals received optical
stimulation (473 nm wavelength, 20 mW, 10 ms duration/pulse, 20 Hz) when they entered
the laser-paired chamber. The stimulation continued until the animal left the laser-paired
chamber. On test day (15 min session), the animals were allowed to explore the apparatus
without optical stimulation. For the CPP comparison between SERT-ChR2-eYFP and
VGluT3-ChR2-eYFP mice, we tested the mice in the absence of light 1 day (test 1), 4 days
(test 2), 7 days (test 3) and 12 days (test 4) after laser conditioning day 2. The participation
of VTA 5-HT3, 5-HT2, and AMPA receptors in CPP was tested by VTA microinjections of
5-HT3 receptor antagonist ondansetron (3 μg/0.3 μl), 5-HT2 receptor antagonist ketanserin
(0.5 μg/0.3 μl) or the AMPA receptor antagonist CNQX (1 μg/0.3 μl). Intra-VTA
microinjection of ACSF served as control. The infusion lasted 1min using a microprocessorcontrolled infusion pump. The microinjector was removed 1 min after infusion, and CPP test
was performed 10 min after injection.

Author Manuscript

Locomotor activity test—SERT-ChR2-eYFP (n = 10) were used to test locomotor
activity in an open field apparatus (40 × 40 × 35 cm, Anymaze, Wood Dale, IL). The
locomotor activity test paradigm consisted of five days. On each day, the mice were
connected to an optical fiber and allowed to move freely in the chamber for 1 min, then
followed by test session. Test session lasted 10 min and was divided into 10 60 s trials.
During odd-numbered trials, continuous laser stimulation was given (473 nm wavelength, 10
mW, 10 ms duration/pulse, 20 Hz). During even-numbered trials, the laser stimulation
remained off. Travel distance and speed of each trail were recorded via a CCD camera
interfaced with ANY-maze behavior tracking software.
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Ultrastructural analysis—Serial thin sections of VTA (bregma −2.92 mm to −3.88 mm)
of the mouse brain atlas of Paxinosand Franklin, VTA (bregma −4.92mm to −6.48 mm) of
the rat brain atlas of Paxinos and Watson were used in this study. Synaptic contacts were
classified according to their morphology and immunolabel, and photographed at a
magnification of 6800–13000 ×. The morphological criteria used for identification and
classification of cellular components observed in these thin sections were as previously
described (Peters et al., 1991). Type I synapses, here referred as asymmetric synapses, were
defined by the presence of contiguous synaptic vesicles within the presynaptic axon terminal
and a thick postsynaptic density (PSD) greater than 40 nm. Type II synapses, here referred
as symmetric synapses, were defined by the presence of contiguous synaptic vesicles within
the presynaptic axon terminal and a thin PSD(Zhang et al., 2015). Serial sections were
obtained to determine the type of synapse. In the serial sections, a terminal containing
greater than 5 immunogold particles were considered as immunopositive terminal. Pictures
were adjusted to match contrast and brightness by using Adobe Photoshop (Adobe Systems
Incorporated, Seattle, WA). The data were collected from 4 rats and 4 SERT::Cre mice. This
experiment was successfully repeated three times. Electron microscopy and confocal
analysis quantification occurred blindly.
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Data analysis of TH cells co-expressing 5-HT3A mRNA of Combination of in
situ hybridization and immunolabeling—Sections were viewed, analyzed, and
photographed with bright field or epiluminescence microscopy using an Olympus VS120
microscope. Single and double-labeled neurons were observed within each traced region at
high power (20 × objective lens) and marked electronically. Subdivisions of the midbrain
dopamine system were traced according to Phillipson(Phillipson, 1979a, b), Halliday
&Törk(Halliday and Törk, 1986), German & Manaye(German and Manaye, 1993). A
neuron was considered to express TH immunoreactivity when its soma was clearly labeled
as brown. ATH immunolabeled neuron was included in the calculation of total population of
TH cells when the stained cell was at least 5 μm in diameter. Pictures were adjusted to match
contrast and brightness by using the program Adobe Photoshop (Adobe Systems
Incorporated, Seattle, WA).
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Statistical analysis—All the statistical analyses applied in fast scan cyclic voltammetry
and electrophysiological studies were performed by paired t test, one-way ANOVA or twoway ANOVA when applicable. We performed two or three-way ANOVA to analyze the
microdialysis and behavioral data when applicable. ANOVA was followed by a post hoc
Newman–Keuls test for multiple comparisons. Statistical analyses were performed with
STATISTICA 9 or GraphPad prism 5. p < 0.05 was considered significant.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Both SERT-Only and SERT-VGluT3 Neurons Synapse on VTA TH Neurons

Author Manuscript

(A) VTA detection of SERT (red), VGluT3 (green), or synaptophysin (blue). Synaptophysin
terminals with SERT (arrowheads) or SERT-VGluT3 (arrow).
(B) VTA frequency of synaptophysin-SERT and synaptophysin-SERT-VGluT3 terminals;
bars represent means ± SEM (four mice, 14,342 counted terminals; 67.66% ± 1.43%
synaptophysin-SERT and 32.34% ± 1.43% synaptophysin-SERT-VGluT3). Paired t test, t(3)
= 12.33, p = 0.0011.
(C and D) SERT-only (C) or SERT-VGluT3 (D) axon terminals (AT) make synapses on VTA
TH-positive neurons. Triple immunolabeling: TH label (gold particles, blue arrowheads);
SERT-immunoperoxidase label (scattered dark material) and VGluT3 label (gold particles,
yellow arrow).
(C) SERT AT lacking VGluT3 (red outline) makes a symmetric synapse (red arrow) with a
TH dendrite (De).
(D) SERT-VGluT3 AT (yellow outline) makes an asymmetric synapse (green arrow) with a
TH dendrite.
Scale bars: 2 μm (A) and 200 nm (C and D).
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Figure 2. SERT-VGluT3 Axon Terminals from DR Make Excitatory Synapses on VTA TH
Neurons that Target the nAcc

(A) Double-injected SERT::Cre mice, AAV5-DIO-ChR2-eYFP in DR and retrograde tracer
Fluoro-Gold (FG) in nAcc.
(A’) Schematic representation of a VTA dopamine neuron projecting to nAcc
(mesoaccumbens neuron) making an asymmetric synapse with a SERT-VGluT3 axon
terminal.
(B-D) VTA confocal microscopy. (B) Detection of TH (blue), FG (red), GFP (green), and
VGluT3 (far-red) in VTA of double-injected SERT::Cre mice. TH-FG (mesoaccumbens)
Cell Rep. Author manuscript; available in PMC 2019 April 30.

Wang et al.

Page 28

Author Manuscript
Author Manuscript

neurons are seen as magenta; yellow rectangle seen at higher magnification in (C) showing a
dendrite (De) from a TH-FG neuron adjacent to an eYFP-VGluT3 input (white-arrows) from
DR-SERT neuron.
(D) Association between the TH-FG dendrite and SERT-VGluT3 terminal (white-arrow) is
better seen after a three-dimensional reconstruction of confocal images. Bregma at −3.40
mm. PBP, parabrachial pigmented area.
(E-G) VTA electron microscopy.
(E) Double-injected SERT::Cre mice, AAV5-DIO-ChR2-mCherry in DR and FG in nAcc.
(F and G) Axon terminals (AT, yellow outlines) from DR SERT neurons (mCherryimmunoperoxidase label; scattered dark material) coexpressing VGluT3 (gold particles,
yellow arrow) make asymmetric synapses (green arrow) on dendrites (magenta outlines).
SERT-VGluT3 terminal makes asymmetric synapses (green arrow) on TH-dendrite De, TH,
gold particle indicated by magenta arrowhead in (F) or on a FG-dendrite (FG, gold particle
indicated by magenta arrowhead in (G).
(H) Double-injected SERT::Cre mice, AAV5-DIO-ChR2-eYFP in DR and CTb-594 in nAcc.
(I) Whole-cell recorded CTb-neuron in lateral VTA neurons confirmed as TH-neurons.
(J) Paired-pulse optical stimulation evoked EPSC was blocked by CNQX (20 μM) (control,
34.8 ± 12.8 pA; CNQX, 2.1 ± 0.2 pA; n = 7, paired t test, t(6) = 2.561, *p = 0.043).
(K) Cell-attached and current-clamp recordings showing increase of VTA neuronal firing by
20-Hz local optical stimulation. Inset: Expanded current-clamp recordings show
synchronization of the first action potential driven by the optical stimulation.
Scale bars: 100 μm in (B), left; 50 μm in (B), right; 1 μm in (C); 200 nm in (F and G); and
10 μm in (I).
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Figure 3. VTA Optical Stimulation of SERT Terminals Expressing ChR2 Evokes 5-HT3
Mediated EPSCs on Dopamine Neurons

(A-F) VTA slice electrophysiological recordings.
(A) Whole-cell recording of a VTA DA neuron during optical stimulation of DR inputs
before (blue) and after (red) blocking 5-HT3 receptors. In green is the current mediated by
5-HT3 receptors (red trace subtracted from blue trace).
(B) Summarized data of the total current and the current mediated by 5-HT3 receptors from
optical stimulation (paired t test, t(5) = 3.432, *p = 0.019, n = 6).

Cell Rep. Author manuscript; available in PMC 2019 April 30.

Wang et al.

Page 30

Author Manuscript
Author Manuscript
Author Manuscript

(C) Summarized difference in rise time between the 5-HT3-mediated current from optical
stimulation and the current remaining after 5-HT3 receptor blockade (*, significantly
different from remainder, one-way repeated-measures ANOVA, F2,8 = 16.72, *p = 0.0014; n
= 5).
(D) Whole-cell recording of a VTA DA neuron and electrical stimulation inputs before
(blue) and after (red) blocking 5-HT3 receptors. In green is current mediated by 5-HT3
receptors.
(E) Summarized total current and current mediated by 5-HT3 receptors from electrical
stimulation (paired t test, t(2) = 4.848, *p = 0.04, n = 3).
(F) Blocking 5-HT3 receptors changes the paired pulse ratio from optical stimulation (paired
t test, t(4) = 3.2, *p = 0.033, n = 5). Data are represented as every data point of nine cells
from four different animals.
(G and H) Activation of DR inputs evokes excitation or inhibition of VTA neurons.
(G) Original recording of VTA, with top trace showing an excited neuron, and bottom trace
showing an inhibited neuron. Blue bars indicate the duration of photoactivation of DR fibers
within the VTA.
(H) Proportion of evoked neural responses.
(I) VTA neurons excited by DR-SERT input activation. Top shows responses of individual
neurons, and bottom shows population average (*, significantly different from
prestimulation, one-way repeated-measures ANOVA, Greenhouse-Geisser corrected, F4,61 =
5.55, p = 0.00065; Neuman-Keuls post hoc test, *p < 0.05; see p value at each time point in
Table S2).
(J) VTA neurons inhibited by photoactivation of DR-SERT fibers. Top shows responses of
individual neurons, and bottom shows population average (*, significantly different from
prestimulation, one-way repeated-measures ANOVA, Greenhouse-Geisser corrected, F4,81 =
10.16, p = 0.000001; Neuman-Keuls post hoc test, *p<0.05; seep value at each time point in
Table S2). Blue bars indicate the duration of photoactivation of DR.
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Figure 4. Optical Stimulation of DR-SERT Neurons or VTA-SERT Inputs Evokes Release of
Dopamine in nAcc Core
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(A) DR viral injection in SERT::Cre mice and optical stimulation of DR-SERT neurons (top)
or VTA DR-SERT fibers (bottom) and fast scan cyclic voltammetry (FSCV) record in nAcc.
(B) Color plot (top) and dopamine concentration trace (bottom) show nAcc core dopamine
release evoked by DR optical stimulation (6 s, 473 nm, 20 mW, 4 ms duration/pulse, 20 Hz).
Inset illustrates characteristic dopamine voltammogram.
(C) Systemic administration of eticlopride increased release of dopamine in nAcc core
evoked by DR optical stimulation confirming the recorded signal as dopamine. Top:
Eticlopride treatment (2 mg/kg, i.p.) increased release of dopamine induced by DR optical
stimulation. Bottom: Corresponding trace indicates the concentration of dopamine (nM) in
response to DR optical stimulation after peripheral administration of eticlopride. Inset
illustrates characteristic dopamine voltammogram. Optical stimulation onset at 5 s is
indicated by blue bars in (B) and (C).
(D) Eticlopride significantly increased release of dopamine in nAcc elicited by optical
stimulation of DR-SERT neurons or VTA-SERT inputs from DR. The significant difference
from baseline (green bars) is indicated by * or # (Student’s t test, t(3) = 5.61, *p = 0.011,
stimulation of SERT neurons [pink bar], n = 4; t(3) = 3.96, #p = 0.029, stimulation SERTinputs [pink bar], n = 4).
(E) Viral injection in DR of SERT::Cre mice, intra-VTA microinjection of 5-HT3A receptor
antagonist ondansetron or AMPA receptor antagonist CNQX, VTA optical stimulation of
DR inputs, and microdialysis in nAcc.
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(F) VTA optical activation of DR-SERT inputs induces nAcc dopamine release that was
abolished by intra-VTA microinjection of ondansetron or CNQX. Each point represents a
10-min dialyzate sampling period (means ± SEM percentage of dopamine baseline, n = 6
each group); blue rectangles indicate the period of optical stimulation. Two-way ANOVA
indicates main-effect time: F11,165 = 11.95, p = 0.000001; group × time interactions: F22,165
= 1.69, p = 0.0334. The 40-min time-point samples were significantly different from all the
baseline time-point samples (#p < 0.05, Newman-Keuls post hoc test [see p value at each
time point in Table S2]; ACSF group: 191.9% ± 28.5%; ondansetron group: 171.3%
± 13.4%; CNQX group: 185.7% ± 30.6%). A single intra-VTA microinjection of
ondansetron or CNQX significantly reduced the enhanced nAcc DA levels elicited by light
stimulation. The 90-min time-point samples from ondansetron group and CNQX group were
significantly different from the ones in the ACSF group (*p = 0.0062, ondansetron versus
ACSF; *p = 0.0086, CNQX versus ACSF, Newman-Keuls post hoc test; ACSF group:
196.9% ± 35.0%; CNQX group: 117.5% ± 4.0%; ondansetron group: 113.7% ± 9.4%).
(G and G’) Expression of 5-HT3A mRNA in VTA TH neurons. TH-positive neurons
(arrows) are shown in (G). TH signal is seen as brown (G and G’) and 5-HT3A mRNA signal
appears as aggregates of green grains (G’) (n = 3). Arrows indicate examples of neurons
coexpressing TH and 5-HT3A mRNA. Arrowheads indicate an example of a neuron
expressing 5-HT3A mRNA but lacking TH. Scale bar: 30 μm.
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Figure 5. VTA Optical Stimulation of DR Inputs Containing ChR2 under the SERT Promoter
Promotes Conditioned Place Preference

(A) Expression of ChR2-eYFP in DR serotonin neurons under the regulation of the SERT
promoter (SERT::Cre mice). Confocal images showing cell-specific ChR2-eYFP expression
(green) in DR serotonin (tryptophan hydroxylase [TPH]) neurons (red).
(B) Confocal images of ChR2-eYFP-positive axons (green, arrowheads) present in the VTA
region. (B’) is a closer view of the box in (B). ml, medial lemniscus.
(C) Diagram showing experimental timeline (top) and diagram of virus injection in the DR
of SERT::Cre mice and VTA optical stimulation of DR SERT terminals (bottom).
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(D) SERT-ChR2-eYFP, but not SERT-eYFP, mice spent more time in the chamber in which
VTA optical stimulation was given during training days. On the test day, SERT-ChR2-eYFP
mice also spent more time in the chamber in which optical stimulation was given on
previous days. Relative time spent in each chamber is represented as means ± SEM (n = 11
each group). Blue rectangles indicate optical stimulation available in the laser-paired
chamber. SERT-ChR2-eYFP mice showed preference for laser-associated chamber on two
laser-paired training days and on test day in comparison with non-laser-associated chamber
(day × chamber × group interaction: F6, 120 = 2.717, p = 0.016, three-way ANOVA; *p =
0.01, **p = 0.005, #p = 0.036, Newman–Keuls post hoc test).
(E) Diagram showing experimental timeline, and diagram of virus injection in the DR of
SERT::Cre mice as well as VTA microinjection of ondansetron, ketanserin, or CNQX, and
VTA optical stimulation of DR SERT terminals.
(F) VTA optical induced real-time or conditioning place preference was blocked by intraVTA injection of ondansetron or CNQX, but not by ketanserin. All treatment groups were
compared with ACSF group (ondansetron versus ACSF, chamber × group interaction: F2, 24
= 4.187, p = 0.028; CNQX versus ACSF, chamber × group interaction: F2, 26 = 5.124, p =
0.013; ketanserin versus ACSF, chamber × group interaction: F2, 26 = 1.48, p = 0.246, threeway ANOVA). Relative time spent in each chamber is represented as means ± SEM. Mice
received a single intra-VTA microinjection of ACSF (n = 7), ondansetron (n = 7), ketanserin
(n = 8) or CNQX (n = 8) 10 min before laser training. Intra-VTA ACSF injected mice
showed preference to the laser-associated chamber on training day and test day in
comparison with non-laser-associated chamber (*p = 0.0009, #p = 0.0008, Newman–Keuls
post hoc test).
Scale bars: 10 μm in (A) and (B’); 40 μm in (B).
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Figure 6. Comparison between the Conditioned Place Preference Induced by the Activation of
VTA SERT-Fibers and the CPP Induced by the Activation of VTA-VGluT3 Fibers
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(A) Diagram showing virus injection into the DR of SERT::Cre or VGluT3::Cre mice, VTA
optical stimulation of DR-SERT-fibers or DR-VGluT3-fibers, and experiment timeline.
(B) On training days, both SERT-ChR2-eYFP and VGluT3-ChR2-eYFP mice spent more
time in the chamber associated with the VTA optical stimulation. In tests 1 and 2, both
SERT-ChR2-eYFP and VGluT3-ChR2-eYFP mice spent more time in the chamber in which
optical stimulation was previously given. In test 3, SERT-ChR2-eYFP, but notVGluT3ChR2-eYFP, mice spent more time in the chamber in which optical stimulation was given on
previous training days. Relative time spent in each chamber is represented as means ± SEM
(n = 10 each group). Blue rectangles indicate optical stimulation available in the laser-paired
chamber on training days 1 and 2. Both SERT-ChR2-eYFP and VGluT3-ChR2-eYFP mice
showed preference for the laser-associated chamber on training days and tests 1 and 2 in
comparison with non-laser-associated chamber(group × day × chamber interaction: F12, 216
= 4.342, p = 0.000001, three-way ANOVA; *p < 0.0001 (see p value for each test in Table
S2), Newman-Keuls post hoc test), but only SERT-ChR2-eYFP mice showed preference for
laser-associated chamber in test 3 in comparison with non-laser-associated chamber (*p =
0.00099, Newman-Keuls post hoc test).
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Figure 7. VTA Synaptic Connectivity by DR Serotonin Neurons
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(A) DR dual-SERT-VGluT3 neurons establish asymmetric synapses mostly on dopamine
neurons (61.17%) and less frequently on nondopamine neurons (38.83%).
(B) DR SERT-only neurons establish symmetric synapses mostly on nondopamine neurons
(63.01%) and less frequently on dopamine neurons (36.99%).
(C) VTA mesoaccumbens dopamine neurons establish asymmetric synapses with a subset
DR SERT-VGluT3 axon terminals, in which, the release of serotonin and glutamate evokes
both dopamine release in the nAcc and reward.
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SOURCE
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Mouse anti-tryptophan hydroxylase antibody

Sigma-Aldrich

CAT# T0678; RRID: AB_261587

Guinea pig anti-VGluT3 antibody

Synaptic System

CAT# 135204; RRID: AB_2619825

Rabbit anti-SERT antibody

Frontier Institute Co. Ltd

CAT# HTT-Rb-Af560–1; RRID:
AB_2571775

Mouse anti-synaptophysin antibody

MilliporeSigma

CAT# MAB368; RRID: AB_94947

Mouse anti-TH antibody

MilliporeSigma

CAT# MAB318; RRID: AB_2201528

Goat anti-GFP antibody

Frontier Institute Co. Ltd

CAT# GFP-Go-Af1480; RRID:
AB_2571574

Rabbit anti-FG antibody

MilliporeSigma

CAT# AB153; RRID: AB_90738

Alexa Fluor 594-affiniPure donkey anti-mouse

Jackson Immunoresearch Laboratories

CAT# 715–585-151; RRID: AB_2340855

Alexa Fluor 488-AffiniPure donkey anti-guinea pic

Jackson Immunoresearch Laboratories

CAT# 706–545-148; RRID: AB_2340472

Alexa Fluor 594-AffiniPure donkey anti-rabbit

Jackson Immunoresearch Laboratories

CAT# 711–585-152; RRID: AB_2340621

Alexa Fluor 647-AffiniPure donkey anti-mouse

Jackson Immunoresearch Laboratories

CAT# 715–605-151; RRID: AB_2340863

Dylight 405-AffiniPure donkey anti-mouse

Jackson Immunoresearch Laboratories

CAT# 715–475-150; RRID: AB_2340839

Alexa Fluor 488-AffiniPure donkey anti-goat

Jackson Immunoresearch Laboratories

CAT# 705–545-147; RRID: AB_2336933

Alexa Fluor 647-AffiniPure donkey anti-guinea pig
(706–605-148

Jackson Immunoresearch Laboratories

CAT# 706–605-148; RRID: AB_2340476

Mouse anti-mCherry

Takara (Clontech)

CAT# 632543; RRID: AB_2307319

Rabbit anti-TH antibody

MilliporeSigma

CAT# AB152; RRID: AB_390204

Biotinylated goat anti-rabbit antibody

Vector Labs

CAT# PK-4001; RRID: AB_2336810

Biotinylated goat anti-mouse antibody

Vector Labs

CAT# PK-4002; RRID: AB_2336811

VECTASTAIN ABC-peroxidase Kit

Vector Labs

CAT# PK-4000; RRID: AB_2336818

Anti-mouse IgG coupled to 1.4 nm gold

Nanoprobes Inc.

CAT# 2001; RRID: not available

Anti-guinea pig IgG Fab’ fragment coupled to 1.4
nm gold

Nanoprobes Inc.

CAT# 2055; RRID: not available

Anti-rabbit IgG coupled to 1.4 nm gold

Nanoprobes Inc.

CAT# 2003; RRID: not available

Cy5 Streptavidin

Jackson Immunoresearch Laboratories

CAT# 016–170-084; RRID: AB_2337245

Cholera toxin B subunit (CTb) conjugated with
Alexa Fluor® 594

Life technologies

CAT# C34777

Fluoro-Gold (FG)

Fluorochrome, LLC

CAT# Patent No. 4,716,905

Ondansetron

Sigma Aldrich

CAT# O3639

CNQX disodium salt hydrate

Sigma Aldrich

CAT# C239

Eticlopride hydrochloride

Tocris a Biotechne Brand

CAT# No1847

Fluoxetine hydrochloride

Tocris a Biotechne Brand

CAT# No 0927

Ketanserin (+)-tartrate salt

Sigma Aldrich

CAT# S006

Y-25130 hydrochloride

Tocris a Biotechne Brand

CAT# No 0380

Durcupan ACM epoxy resin

Electron Microscopy Sciences

CAT# 14040

Nanoprobe Silver Kit

Nanoprobes Inc.

CAT# 2012

Antibodies

Chemicals, Peptides, and Recombinant Proteins
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Mouse: C57BL/6J

The Jackson Laboratory

CAT# 5657312; MGI:5657312

Serotonin transporter (SERT)::Cre mice

Mutant Mouse Regional Resource Centers

RRID: MMRRC:017260-UCD

GraphPad Prism 5.0

GraphPad Software, Inc

RRID: SCR_002798

Adobe Photoshop

Adobe Systems Incorporated

RRID: SCR_014199

ANY-maze video tracking system

Stoelting Co.

RRID: SCR_014289

Imaris microscopy software

Bitplane, Inc.

RRID: SCR_007370

Statistica 9

StatSoft, Inc.

RRID: SCR_014213

Experimental Models: Organisms/strains
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